hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06267677 id: 2007/3928 briefTitle: Efficacy of Liquid Versus Powder Protein Supplementation to Optimize Protein Intake After Bariatric Surgery overallStatus: COMPLETED date: 2008-01-02 date: 2008-04-18 date: 2009-03-06 date: 2024-02-20 date: 2024-02-20 name: Hospital Clinic of Barcelona class: OTHER briefSummary: The goal of this randomized control trial is to compare the effect of a liquid formula rich in nutrients and low in calories (supplement) with the progressive diet with conventional foods that we usually recommend in patients after surgery. The main question it aims to answer is if the addition of a high-protein, volume-controlled nutritional supplement as a fundamental part of the diet during the first two months after surgery will preserve the patient's nutritional status and prevent the appearance of nutritional deficits and associated complications.
* Gastrointestinal tolerance through self-registration of symptoms. Researchers will compare the effect of a complete hypocaloric liquid formula group with the usual progressive diet group to see if they achieve the protein intake goal established for patients after obesity surgery, preservation of nutritional status and lean mass during the rapid phase of weight loss and the gastrointestinal tolerance during the first two months after surgery. conditions: Body Composition conditions: Obesity conditions: Protein Supplementation conditions: Bariatric Surgery Candidate conditions: Weight Loss studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 50 type: ACTUAL name: High protein liquid formula measure: protein intake measure: evaluate nutritional deficiencies measure: Tolerance sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06267664 id: PI-GR-23-3263 briefTitle: Real-world Effectiveness and Tolerability of Triptans-Ditans-Gepants (TRIDIGEP) acronym: TRIDIGEP overallStatus: RECRUITING date: 2023-12-04 date: 2024-09-30 date: 2024-12-01 date: 2024-02-20 date: 2024-02-21 name: Hospital Clínico Universitario de Valladolid class: OTHER briefSummary: Migraine is the third most prevalent disease and the leading reason of years lived with disability in the most productive years of the life. Migraine associated disability can be alleviated by acute and preventive treatment. The migraine landscape has changed recently, with the approval of novel acute treatments, including oral Calcitonin gene-related peptide antagonists, the gepants (Rimegepant, Ubrogepant, Zavegepant) and 5-HT-1F antagonists, the Ditans (Lasmiditan). These have joined Triptans as acute "migraine-specific" drugs.
The endpoints recommended by the International Headache Society will be employed, including: 1) Pain freedom; 2) Absence of the most bothersome symptom; 3) Sustained pain freedom; 4) Total freedom from migraine; 5) Headache relief; 6) Duration of attacks; 7) Time lost due to an attack; 8) Need of rescue medication. The study endpoints will be assessed at 2, 8 and 24 hours after the acute drug use. Data will be collected by the patients themselves, with a validated data collection instrument within a RedCap questionnaire, using QR codes. conditions: Migraine conditions: Migraine Disorders conditions: Migraine With Aura conditions: Headache Disorders studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1500 type: ESTIMATED name: Patients with migraine treated with triptans, Lasmiditan or Gepants measure: Pain freedom at 2 hours measure: Absence of the most bothersome symptom measure: Pain freedom at 8 hours measure: Pain freedom at 24 hours measure: Sustained pain freedom measure: Total freedom from migraine at 2 hours measure: Total freedom from migraine at 8 hours measure: Total freedom from migraine at 24 hours measure: Headache relief at 2 hours measure: Headache relief at 8 hours measure: Headache relief at 24 hours measure: Time to meaningful relief measure: Time to pain freedom measure: Time to migraine freedom measure: Need of rescue medication at 2 hours measure: Need of rescue medication at 8 hours measure: Need of rescue medication at 24 hours measure: Tolerability of the drugs measure: Response predictors at 2 hours measure: Response predictors at 24 hours measure: Tolerability predictors measure: Time lost due to an attack sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital Clínico Universitario de Valladolid status: RECRUITING city: Valladolid zip: 47010 country: Spain name: David Garcia Azorin, MD, PhD role: CONTACT phone: +34665872228 email: davilink@hotmail.com name: Yesica González Osorio role: CONTACT phone: 634330426 email: yesgonzalezosorio@outlook.com lat: 41.65518 lon: -4.72372 hasResults: False
nctId: NCT06267651 id: Steroid in ulcerative colitis briefTitle: Value Of ACE Index (Albumin, CRP And Endoscopy) In Predicting Intra Venous Steroid Response In Acute Severe Ulcerative Colitis In Assiut University Hospitals overallStatus: NOT_YET_RECRUITING date: 2025-01 date: 2026-06 date: 2027-01 date: 2024-02-20 date: 2024-02-20 name: Assiut University class: OTHER briefSummary: 1. Determine if the ACE index can predict resoponse to I V steroid in Acute severe ulcerative colitis
2. identify on admission a high-risk population who may beneft from earlier second line medical treatment or surgical intervention. ( steroid non responder groups ) conditions: Early Detection of Complication of Ulcerative Colitis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 95 type: ESTIMATED measure: Early prevention of complication of ulcerative colitis sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT hasResults: False
nctId: NCT06267638 id: Chomthong hospital, Thailand briefTitle: Comparison of Postoperative Pain Score Between Perioperative Intravenous Ketamine and Placebo in Patients Undergoing Unilateral Total Knee Arthroplasty Under General Anesthesia overallStatus: RECRUITING date: 2024-01-22 date: 2025-12-31 date: 2025-12-31 date: 2024-02-20 date: 2024-03-12 name: Ministry of Health, Thailand class: OTHER_GOV briefSummary: The goal of this clinical trial is to compare postoperative pain score between perioperative intravenous ketamine and placebo in patients undergoing unilateral total knee arthroplasty under general anesthesia. The main question\[s\] it aims to answer are:
* Can perioperative intravenous ketamine reduce morphine consumption in postoperative 24 hours, length of hospital stay, first time to receive opioid and side effect or complication from ketamine and opioid better than no administration of Ketamine in patients undergoing Unilateral total knee arthroplasty under general anesthesia? Participants will receive intravenous ketamine intraoperative TKA and comparison group will receive placebo that is normal saline. Researchers will compare perioperative intravenous ketamine and placebo to see postoperative pain score, morphine consumption in postoperative 24 hours, length of hospital stay, first time to receive opioid and side effect or complication from ketamine and opioid. conditions: Knee Osteoarthritis studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 100 type: ESTIMATED name: Ketamine group name: Placebo group measure: Postoperative pain score at rest and movement measure: First time to receive intravenous analgesic drug measure: Morphine consumption measure: Length of hospital stay measure: side effect and complication from ketamine and opioid sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Chomthong hospital status: RECRUITING city: Chiangmai zip: 50160 country: Thailand name: Numphung Sukantarat, master role: CONTACT phone: 66855426519 email: phuang_007@yahoo.com lat: 18.79038 lon: 98.98468 hasResults: False
nctId: NCT06267625 id: Elderly Individuals briefTitle: Physical Impairments in Elderly Individuals overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2026-03-15 date: 2026-12-15 date: 2024-02-20 date: 2024-02-20 name: Izmir Democracy University class: OTHER briefSummary: There are no studies in the literature reporting the dyspnea, posture, strength, physical activity, functional mobility and balance in elderly individuals. The aims of this observational study are; 1) to evaluate dyspnea, posture, strength, physical activity, functional mobility and balance in elderly individuals, 2) to reveal the relationships between these parameters of research group. conditions: Aging Disorder studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 50 type: ESTIMATED name: Physical Evaluations of individuals measure: Dyspnea score measure: Posture score measure: Cough strength measure: Handgrip strength measure: Functional mobility score measure: Physical activity score measure: Functional Mobility score measure: Balance score measure: Cognitive function score sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: Izmir Democracy University city: İzmir zip: 35140 country: Turkey name: GÜLŞAH BARĞI, Assoc.Dr. role: CONTACT phone: +90 531 793 8766 email: gulsahbargi35@gmail.com name: ESRA SUDE AKIN, BSc role: CONTACT phone: +90 543 581 4690 email: esrasudeakin@gmail.com lat: 38.41273 lon: 27.13838 hasResults: False
nctId: NCT06267612 id: KY20231109-11 briefTitle: Corheart 6 LVAS Long-term Follow-up Study overallStatus: NOT_YET_RECRUITING date: 2024-02-10 date: 2030-06-30 date: 2030-06-30 date: 2024-02-20 date: 2024-02-20 name: Nanjing First Hospital, Nanjing Medical University class: OTHER briefSummary: The purpose of this clinical study is to explore the long-term efficacy and safety of the Corheart 6 Left Ventricular Assist System (LVAS) as a treatment for patients with advanced heart failure.
The study will be a single-arm, prospective, single-center, non-blinded, and non-randomized study with a follow-up duration of five years. conditions: Heart Failure studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Corheart 6 Left Ventricular Assist System measure: Device implantaion success rate at 24 months post-implantation measure: Quality of Life as measured by the Kansas City Cardiomyopathy Questionnaire-23 (KCCQ-23) measure: Quality of Life as measured by the EuroQoL-5D-5L (EQ-5D-5L) questionnaire measure: Functional status as measured by the Six Minute Walk Test (6MWT) measure: Functional status as measured by the New York Heart Association (NYHA) Classification measure: Stroke severity as assessed with the National Institutes of Health Stroke Scale (NIHSS) score measure: Stroke severity as assessed by the modified Rankin Scale (mRS) score measure: Adverse events measure: Device-related re-operations measure: Device-related re-hospitalizations measure: Overall survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Nanjing First Hospital city: Nanjing state: Jiangsu country: China name: Zhibing Qiu role: CONTACT email: qiuzhibing2009@163.com lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06267599 id: ACAR-Style Bladder Suture briefTitle: Bladder Suture in Uterus-Sparing Surgery and Hysterectomy for Placenta Percreta overallStatus: COMPLETED date: 2023-09-01 date: 2023-12-01 date: 2024-01-01 date: 2024-02-20 date: 2024-02-20 name: Necmettin Erbakan University class: OTHER briefSummary: This study aimed to evaluate the short-term and long-term complications of placenta percreta with bladder invasion. This evaluation focuses on cases where bladder dissection and ACAR-style bladder sutures were applied in cases of placenta percreta with bladder invasion that underwent uterine-sparing surgery or hysterectomy. conditions: Placenta Percreta conditions: Bladder Injury conditions: Sutures studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 81 type: ACTUAL name: ACAR-Style Bladder Suture measure: Comparison of intraoperative bleeding and complication rates of the two groups measure: Comparison of postoperative bleeding between two groups measure: Comparison of complication rate between two groups sex: FEMALE minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Cemre Alan city: Konya country: Turkey lat: 37.87135 lon: 32.48464 hasResults: False
nctId: NCT06267586 id: PN23.007 briefTitle: Effects of PeptiSleep in Healthy Males and Females With Mild to Moderate Sleep Impairment overallStatus: RECRUITING date: 2024-04-08 date: 2024-12-30 date: 2025-02-20 date: 2024-02-20 date: 2024-04-24 name: Nuritas Ltd class: INDUSTRY name: RDC Clinical Pty Ltd briefSummary: Examining the effects of PeptiSleep, a plant-based sleep aid, in healthy males and females with mild to moderate sleep impairment conditions: Sleep studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized, single-blind, placebo-controlled, parallel dose response study conducted over 70 days primaryPurpose: OTHER masking: SINGLE maskingDescription: Participants will be unaware of arm allocation however as each arm contains a different number of capsules to be consumed, the investigator will be aware of the arm allocation whoMasked: PARTICIPANT count: 60 type: ESTIMATED name: PeptiSleep name: Placebo MCC micro-crystalline cellulose measure: Safety and Tolerability of a dose range of PeptiSleep via adverse event reporting measure: Safety via electrolytes and liver function tests measure: Sleep Quality via Leeds Sleep Evaluation Questionnaire measure: Insomnia severity via the Insomnia Severity Index Questionnaire measure: Sleep onset time via self-reported recording in a Sleep Diary measure: Sleep pattern via self-reported recording in a Sleep Diary measure: Daytime Sleepiness via the Epworth Sleepiness Scale measure: Stress via the Perceived Stress Scale measure: Stress via self reported Profile of Mood States Questionnaire measure: Anxiety via self-reported Beck Anxiety Inventory questionnaire measure: Stress via Salivary cortisol test measure: Alertness via Reaction Time Test measure: Circadian cycles via melatonin and serotonin via blood test measure: Markers associated with inflammation via blood test measure: Sleep onset latency via wearable sleep tracker measure: Total sleep time spent in sleep phases via wearable sleep tracker measure: Blood pressure via blood pressure machine measure: Heart rate via blood pressure machine measure: Body Temperature via wearable sleep tracker measure: BMI via height and weight measurements measure: Bedtime via wearable sleep tracker measure: Total time awake via wearable sleep tracker measure: Sleep quantity via wearable sleep tracker measure: Sleep efficiency via wearable sleep tracker measure: Sleep score via wearable sleep tracker measure: Nocturnal heart rate via wearable sleep tracker measure: Heart Rate variability via wearable sleep tracker measure: Blood Oxygen sensing via sleep tracker measure: Respiratory rate via sleep tracker measure: Daily Readiness Score via sleep tracker sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: RDC Clinical status: RECRUITING city: Brisbane state: Fortitude Valley Queensland zip: 4006 country: Australia name: Amanda Rao role: CONTACT name: Amanda Rao role: PRINCIPAL_INVESTIGATOR lat: -27.46794 lon: 153.02809 hasResults: False
nctId: NCT06267573 id: Kerolos protocol briefTitle: Thoracoabdominal Aortic Aneurysms overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2025-09-15 date: 2026-09-10 date: 2024-02-20 date: 2024-02-20 name: Assiut University class: OTHER briefSummary: Evaluation of the effectiveness of the different modalities for treatment of thoracoabdominal aortic aneurysms. FEVAR and BEVAR devices are widely used now due to its feasability and wide range of use . We aim to evaluate the effectiveness of these new devices in the management of TAAA conditions: Thoracoabdominal Aortic Aneurysm studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: Fenestrated and branched endovascular devices for TAAA measure: Successful cannulation of the target vessels with complete in-line flow to target organs. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06267560 id: CTQJ230A12303 briefTitle: Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD overallStatus: NOT_YET_RECRUITING date: 2024-05-27 date: 2027-06-21 date: 2027-06-21 date: 2024-02-20 date: 2024-02-20 name: Novartis Pharmaceuticals class: INDUSTRY briefSummary: Study CTQJ230A12303 is a randomized, double-blind placebo-controlled, Phase IIIb study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) 80 mg s.c. QM compared with placebo s.c. QM in US Black/African American and Hispanic participants with established ASCVD and elevated levels of Lp(a) who are treated for cardiovascular (CV) risk factors according to local practice/guidelines for the reduction of cardiovascular risk. conditions: Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Eligible participants will be randomized after the screening period or Guideline recommended SOC implementation period (if needed) in a 2:1 ratio to subcutaneous injections of pelacarsen (TQJ230) 80 mg QM or placebo QM either to be self-administered or administered by caregiver or site personnel approximately every 30 days for up to 12 months. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 400 type: ESTIMATED name: TQJ230 name: Placebo measure: Change in log-transformed Lp(a) concentration from baseline at week 52 measure: Incidence proportion of study discontinuations due to TEAEs measure: Incidence proportion of Treatment emergent adverse events (TEAEs) of special interest sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06267547 id: 2023P003522 briefTitle: Healthy Activities Improve Lives (HAIL) acronym: HAIL overallStatus: RECRUITING date: 2024-04-23 date: 2026-12-01 date: 2027-02-01 date: 2024-02-20 date: 2024-04-29 name: Massachusetts General Hospital class: OTHER name: National Institute on Aging (NIA) briefSummary: The investigators have developed an online platform to support the 8-week, F\&S! exercise program called the Healthy Activity Improves Lives (HAIL) online platform. The aim of this study is to perform a cluster randomization of four racially diverse churches or senior centers to either the standard F\&S! program, or the combined HAIL Online Platform + F\&S! program to examine the efficacy of the HAIL online platform + F\&S! program for older adults in black communities. conditions: Physical Activity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 120 type: ESTIMATED name: HAIL Online Platform name: Fit and Strong! Program measure: Feasibility and Retention measure: Acceptability measure: Acceptability (Feedback Form) measure: Acceptability (Exit Interviews) measure: Changes in Physical Activity (Steps) measure: Changes in Physical Activity (MVPA) measure: Changes in Aerobic Capacity measure: Changes in Physical Strength measure: Motivation to Change measure: Utilization of Healthcare Resources measure: Fall History measure: Chronic Conditions measure: Changes in Overall Wellbeing measure: Changes in Depression measure: Changes in Anxiety measure: Changes in Physical Functioning measure: Changes in Social Isolation measure: Changes in Confidence in Exercises measure: Satisfaction with program measure: Satisfaction with program measure: Use of online program measure: Use of online program sex: ALL minimumAge: 60 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Roslindale Baptist Church status: RECRUITING city: Boston state: Massachusetts zip: 02131 country: United States name: Lydia Townsend role: CONTACT lat: 42.35843 lon: -71.05977 hasResults: False
nctId: NCT06267534 id: YCH briefTitle: Mindfulness-based Mobile Applications Program overallStatus: COMPLETED date: 2022-09-09 date: 2022-09-22 date: 2022-09-22 date: 2024-02-20 date: 2024-02-20 name: Yu-Chien Huang class: OTHER briefSummary: The goal of this type of study: quasi-experimental clinical trial . The purpose of this study is to explore the effects of applying mindfulness-based mobile applications program to maintaining mental health of emergency nurses during providing care to COVID-19 patients. The main question\[s\] it aims to answer are:
Participants will Mindfulness-based mobile device is provided to experimental group as assistance for 2 weeks. In the contrary, no intervention measure was assigned in the control group. Scale exam was performed before and after the program in both groups at the same time. conditions: COVID-19 conditions: Cell Phone Use conditions: Nurse conditions: Mental Health studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: PARTICIPANT count: 102 type: ACTUAL name: mindfulness-based mobile applications program measure: The impact of mindfulness-based mobile device assistance program on the care stress of emergency nursing staff caring for COVID-19 patients measure: Effects of mindfulness-based mobile device assistance program on psychological distress among emergency nursing staff caring for COVID-19 patients measure: Effects of a mindfulness-based mobile device-assisted program on compassion fatigue among emergency nursing staff caring for COVID-19 patients sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Yu-Chien Huang city: Taipei state: Zhongzheng District zip: 100 country: Taiwan lat: 25.04776 lon: 121.53185 hasResults: False
nctId: NCT06267495 id: EOCXLFE briefTitle: Epithelium-on Cross-linking Versus Observation of Fellow Eyes of Patients With Unilateral Clinically Evident Keratoconus overallStatus: COMPLETED date: 2017-01-01 date: 2024-01-31 date: 2024-01-31 date: 2024-02-20 date: 2024-02-20 name: Assiut University class: OTHER briefSummary: Keratoconus (KC) is a bilateral asymmetric progressive corneal degenerative disease. The management of young patients, diagnosed with clinically evident KC in one eye and with no clinical signs of KC in the other eye, represents a real challenge for many ophthalmologists.
The aim of the current study is to investigate the effectiveness and safety of epithelium-on accelerated CXL to stabilize the eye with no clinical signs of KC, in young patients with unilateral clinically evident KC, compared with standard care and follow-up only. conditions: Keratoconus studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: RETROSPECTIVE count: 40 type: ACTUAL name: Epithelium-on corneal cross-linking (epi-on CXL) measure: Steep keratometry value measure: Maximum keratometry value measure: Corrected distance visual acuity sex: ALL minimumAge: 12 Years maximumAge: 30 Years stdAges: CHILD stdAges: ADULT facility: Tiba Eye Center city: Assiut zip: 71516 country: Egypt lat: 27.18096 lon: 31.18368 hasResults: False
nctId: NCT06267482 id: 122311 briefTitle: Using ROSA for Challenging The TKA Standard of Care overallStatus: RECRUITING date: 2024-04-16 date: 2025-04 date: 2025-06 date: 2024-02-20 date: 2024-04-18 name: Lawson Health Research Institute class: OTHER name: Zimmer Biomet briefSummary: This is a prospective, randomized controlled trial using the cruciate retaining, MC Persona to comparing the conventional TKA to ROSA assisted TKA. Patients will be randomized to one of three study trial arms.